Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents

• Main Authors: Pio Lopez (Author), Lulu Bravo (Author), Erik Buntinx (Author), Charissa Borja-Tabora (Author), Hector Velasquez (Author), Edith Johana Rodriquez (Author), Camilo A. Rodriguez (Author), Josefina Carlos (Author), May Emmeline B. Montellano (Author), Edison R. Alberto (Author), Milagros Salvani-Bautista (Author), Yung Huang (Author), Branda Hu (Author), Ping Li (Author), Htay Htay Han (Author), Carmen Baccarini (Author), Igor Smolenov (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

We previously demonstrated the efficacy of the COVID-19 vaccine candidate, SCB-2019, in adults in the SPECTRA phase 2/3 efficacy study. We extended the study to include 1278 healthy 12-17-year-old adolescents in Belgium, Colombia, and the Philippines who received either two doses of SCB-2019 or plac...